{
  "docId": "019f6b8f-1840-747c-b048-7afedf31e31d",
  "docSlug": "jarvis-ey-how-fit-is-your-capital-allocation-strategy",
  "documentTitle": "EY How fit is your capital allocation strategy",
  "authorId": "ey-how-fit-is-your-capital-allocation-strategy",
  "authorName": null,
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": null,
  "aspectRatio": null,
  "pageNumber": 9,
  "pageCount": 24,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "peer_benchmark",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 12,
  "notes": "Ex-Gilead biotech margins are provided as a footnote.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019f6b8f-1840-747c-b048-7afedf31e31d/9",
  "deckHref": "/decks/019f6b8f-1840-747c-b048-7afedf31e31d",
  "deckJsonHref": "/decks/019f6b8f-1840-747c-b048-7afedf31e31d.json",
  "deckAnchorHref": "/decks/019f6b8f-1840-747c-b048-7afedf31e31d#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "chart",
      "text": null,
      "attrs": null,
      "subkind": "bar-grouped",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1314546-3c17-4474-9590-9704b7a1debb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.75,
        "y": 0.4
      },
      "kind": "legend",
      "text": "Big pharma; Biotech*; Specialty pharma (incl. generics)",
      "attrs": null,
      "subkind": "legend",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "376e4a08-0df9-4c43-aaf6-88bdc3701ce1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "other",
      "text": "* Ex-Gilead biotech margins: 41% Q1 2015, 34% 2014. Source: EY and Capital IQ. Generics companies have been included in specialty pharma for this comparison.",
      "attrs": null,
      "subkind": "source-note",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "378eac3e-1ee4-4e70-b15f-6bb2579186c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Operating margins: big pharma rebounds but still lags biotech",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d920ad8e-8799-4d90-8576-fad58c32ab0f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "c79882cc-7c98-463d-a442-858530c3e1bb",
      "evidence": "legend/legend: Big pharma; Biotech*; Specialty pharma (incl. generics)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 15,
      "from": 7,
      "beatId": "2ee61659-cd45-4e64-8c84-7f31031fa91a",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides data and analysis to support its claims.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}